Krishna Institute of Medical SciencesQ1 FY24

Krishna Institute of Medical Sciences Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹768.3P/E: 158.8Market Cap: ₹32.3K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Telangana and Andhra Pradesh clusters continue revenue growth at 15% YoY, with room for new specialty additions (oncology, mother & child care, interventional procedures) to drive further growth.
  • Incremental bed additions of ~1500 beds in Andhra and Telangana over 24-36 months, maintaining occupancy around 70-75%.
  • Sunshine and Nagpur hospitals expected to scale up with improved occupancy and doctor additions, contributing positively to revenue.
  • New facilities in Bangalore (750 beds) to start operations between Q1 and Q2 FY25, with significant capex (~INR 650 crores).
  • Thane and Nashik projects progressing with expected capacity additions.
  • ARPOB (Average Revenue Per Occupied Bed) expected to grow at a blended 3-5% rate, driven mainly by new clinical therapies and pricing from insurance.
  • EBITDA margins anticipated to improve as new facilities mature, with incremental revenue converting 40% directly to EBITDA in key clusters.

See what Krishna Institute of Medical Sciences management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
  • Finance cost has doubled this quarter mainly due to drawing down limits for Sunshine units.
  • Management stated financing options include using existing limits for capex or drawing from available profits.
  • No definitive commitment or plan for fresh debt or equity issuance was shared.
  • Expansion projects are primarily funded by internal accruals or existing credit limits.
  • The company appears focused on operational growth and capacity ramp-up rather than new external fundraising currently.

See what Krishna Institute of Medical Sciences management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex will start mostly from next fiscal year, with significant investment planned for new hospitals and facility expansions.
  • Bangalore: Two hospitals with 750 beds combined, INR 650 crores total outlay (~INR 80 lakhs per bed); one asset 50% owned, other on revenue share model.
  • Thane project: INR 400 crores capex, with construction underway and transaction closure with investor expected soon; operational by Q1 or Q2 of next fiscal.
  • Nashik hospital projected to be operational by Q4 of current financial year or early Q1 next year.
  • Kondapur expansion: Incremental 400 beds planned to begin two years from now.
  • Expansion in Andhra with new oncology centers and mother & child care units across multiple facilities.
  • Emphasis on ramping up Sunshine and Nagpur hospitals, including shifting OPD/IPD in Sunshine from August.
  • Corporate overhead costs currently impacting Telangana cluster margins due to expansion activities.

Track Krishna Institute of Medical Sciences — get its next earnings analysis in your feed

How does Krishna Institute of Medical Sciences rank vs peers in Healthcare Services?

Pro feature
ThisKrishna Institute of Medical Sciences
Rev 3Mar 3

How does Krishna Institute of Medical Sciences rank in Healthcare Services?

Compare Krishna Institute of Medical Sciences against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →